HHS pauses sotrovimab distribution to all regions 

The Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response has stopped distributing the COVID-19 monoclonal antibody sotrovimab because the BA.2 omicron variant now predominates in every U.S. state and territory. The Food and Drug Administration recently revised the emergency use authorization for sotrovimab to exclude regions where the BA.2 variant predominates because the authorized dose was unlikely to be effective against it, and recommends that health care providers use alternative authorized therapies until further notice.